查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2148885

大腸直腸癌治療市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Colorectal Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 132 Pages | 商品交期: 2-3個工作天內

價格

大腸直腸癌治療市場成長要素

全球大腸直腸癌治療市場預計到2025年將達到144.1億美元，從2026年的152.6億美元成長到2034年的241億美元，2026年至2034年的複合年成長率（CAGR）為5.88%。推動該市場成長的因素包括大腸直腸癌發病率的上升、公眾意識的提高、診斷能力的提升以及創新癌症療法的持續發展。預計到2025年，北美將以44.60%的市佔率引領全球市場。

大腸直腸癌涵蓋多種主要疾病類型，例如大腸直腸腺癌和胃腸道類癌。隨著診斷率的提高和對有效治療方法的需求日益成長，製藥公司正在拓展其抗癌藥物研發管線，並推出先進的療法。

市場規模及預測

年度市場規模

2025年將達144.1億美元

2026年將達152.6億美元

2034年將達241億美元

大腸直腸癌治療市場趨勢

大腸直腸癌治療市場正日益受到標靶治療、免疫療法、先進診斷技術和個人化治療方案的影響。人們對大腸直腸癌症狀和風險因素的認知不斷提高，推動了早期診斷的普及。此外，製藥公司也在加大研發投入，以滿足尚未滿足的醫療需求，並開發能夠改善患者預後的治療方法。

市場促進因素

醫藥領域日益成長的意識與創新

人們對大腸直腸癌的認知不斷提高，以及對早期診斷重要性的日益重視，推動了對治療的需求。創新藥物和聯合治療的推出，正在重振市場。特別是標靶治療，為合格的患者提供了更精準的治療選擇，發揮著至關重要的作用。

發病率上升和未滿足的需求

大腸直腸癌發病率的不斷上升以及由此導致的死亡率升高，使得有效治療方法的需求日益迫切。持續的臨床研究、新產品的上市以及先進療法的研發，正致力於滿足不同患者群尚未滿足的醫療需求。

市場限制與挑戰

治療成本不斷上漲以及價格更低廉的學名藥日益普及，可能會限制某些治療領域的市場擴張。尤其是化療，面臨來自學名藥的競爭壓力。此外，先進療法需要大量的臨床研究、監管批准和巨額投資，這會增加研發成本和商業化風險。

市場機遇

標靶治療、免疫療法、個人化醫療和聯合治療的日益普及帶來了巨大的市場機會。新興經濟體醫療保健支出的成長和腫瘤基礎設施的改善，預計將進一步擴大大腸直腸癌治療的覆蓋範圍。此外，日益便利的數位化醫療生態系統和不斷發展的數位化醫療生態系統，也為線上藥局的興起創造了新的機會。

細分分析

透過治療方法

市場細分包括標靶治療、免疫療法、化療和其他療法。標靶治療佔主導地位，以Avastin）、艾維泰克斯（Elvitex）和Stivarga）等藥物為代表，預計到2025年市場規模將達到98.5億美元。免疫療法和化療仍然是重要的治療類別。

按癌症類型

該市場涵蓋大腸直腸腺癌、胃腸道類癌及其他癌症。大腸直腸腺癌在結直腸癌病例中佔很大比例，並且由於其進行性病變帶來的治療需求，預計該市場將顯著成長。

透過分銷管道

市場細分為醫院藥局、零售藥局、網路藥局和其他通路。由於許多大腸直腸癌藥物需要專業的診斷和給藥，預計到2025年，醫院藥房將佔據市場主導地位，市場佔有率達49.30%。網路藥局因其便利性和易用性，預計將實現強勁成長。

區域分析

到2025年，北美將佔全球市場佔有率的44.60%，成為領先的區域市場。積極的臨床研究、先進的診斷技術、新產品的推出以及較高的治療方案普及率正在推動該地區的成長。

亞太地區預計將迎來強勁成長，這主要得益於癌症發病率上升、醫療基礎設施改善、可支配收入增加以及公眾健康意識提高。到2025年，日本市場預計將達到10.3億美元，中國市場也有望強勁成長。

受高發病率和先進療法日益普及的推動，歐洲預計將迎來顯著成長。英國、法國和西班牙是關鍵市場。

預計拉丁美洲將保持穩定成長，而中東和非洲的成長最初預計相對有限，但從長遠來看，其潛力有望擴大。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章：主要考慮因素

  • 2025年主要國家大腸癌盛行率
  • 管道分析，主要公司
  • 主要行業趨勢
  • 新產品發布
  • 擴大大腸直腸癌診斷領域的研究和開發工作

第5章：2021-2034年全球大腸直腸癌治療市場分析、洞察與預測

  • 主要發現與總結
  • 市場分析、洞察與預測：按療法分類。
    • 標靶治療
    • 免疫療法
    • 化療
    • 其他
  • 市場分析、洞察與預測：按癌症類型分類
    • 結腸腺癌
    • 胃腸道類癌
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美大腸直腸癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲大腸直腸癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區大腸直腸癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲結直腸癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲大腸直腸癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025 年）
  • 競爭對手儀錶板
  • 主要公司比較分析
  • 公司簡介
    • Genentech, Inc.
    • Eli Lilly and Company
    • Pfizer Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Bristol Myers Squibb
    • Merck Sharp & Dohme Corp.
    • Taiho Pharmaceutical（Otsuka Pharmaceutical Co., Ltd.）
    • Bayer AG
    • Regeneron Pharmaceuticals, Inc.
    • Novartis AG
    • Ipsen Biopharmaceuticals, Inc.

第12章附錄

Product Code: FBI101945

Growth Factors of colorectal cancer therapeutics Market

The global colorectal cancer therapeutics market was valued at USD 14.41 billion in 2025 and is projected to grow from USD 15.26 billion in 2026 to USD 24.10 billion by 2034, registering a CAGR of 5.88% from 2026 to 2034. The market is being driven by the increasing prevalence of colorectal cancer, rising awareness, improved diagnostic capabilities, and continuous development of innovative oncology therapies. North America dominated the market with a 44.60% share in 2025.

Colorectal cancer includes major disease forms such as colorectal adenocarcinoma and gastrointestinal carcinoid tumors. Increasing diagnosis rates and the need for effective treatments are encouraging pharmaceutical companies to expand their oncology pipelines and introduce advanced therapeutics.

Market Size and Forecast

Year Market Size

2025 USD 14.41 Billion

2026 USD 15.26 Billion

2034 USD 24.10 Billion

Colorectal Cancer Therapeutics Market Trends

The colorectal cancer therapeutics market trends are increasingly influenced by targeted therapies, immunotherapies, advanced diagnostics, and personalized treatment approaches. Greater awareness of colorectal cancer symptoms and risk factors is supporting earlier diagnosis. Pharmaceutical companies are also increasing R&D investments to develop therapies that address unmet treatment needs and improve patient outcomes.

Market Drivers

Increasing Awareness and Drug Innovation

Growing awareness about colorectal cancer and the importance of early diagnosis is supporting demand for therapeutics. The introduction of innovative drugs and combination treatment approaches is strengthening the market. Targeted therapies have become particularly important because they provide more specialized treatment options for eligible patients.

Rising Disease Prevalence and Unmet Treatment Needs

The increasing prevalence of colorectal cancer and its associated mortality is creating substantial demand for effective treatments. Continuous clinical research, novel product launches, and development of advanced therapies are helping address unmet medical needs across different patient populations.

Market Restraints and Challenges

High treatment costs and the increasing availability of lower-priced generic medicines can limit market expansion in certain therapy categories. Chemotherapy, in particular, faces competitive pressure from generics. Additionally, advanced therapeutics require extensive clinical research, regulatory approvals, and significant investment, which can increase development costs and commercialization risks.

Market Opportunities

The growing adoption of targeted therapy, immunotherapy, personalized medicine, and combination treatments offers significant market opportunities. Increasing healthcare expenditure and improving oncology infrastructure in emerging economies can further expand access to colorectal cancer treatments. Online pharmacy adoption is another emerging opportunity because of its convenience and expanding digital healthcare ecosystem.

Segmentation Analysis

By Therapy

The market is segmented into Targeted Therapy, Immunotherapy, Chemotherapy, and Others. Targeted therapy held the leading position and reached USD 9.85 billion in 2025, supported by therapies such as Avastin, Erbitux, and Stivarga. Immunotherapy and chemotherapy also remain important treatment categories.

By Cancer Type

The market includes Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others. Colorectal adenocarcinoma is expected to experience significant growth due to its large share of colorectal cancer cases and the treatment requirements associated with aggressive disease forms.

By Distribution Channel

The market is divided into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Hospital pharmacies dominated with a 49.30% share in 2025, as many colorectal cancer medicines require specialist diagnosis and administration. Online pharmacies are expected to experience strong growth due to convenience and accessibility.

Regional Analysis

North America was the leading regional market in 2025, accounting for 44.60% of the global market. Strong clinical research, advanced diagnostics, product launches, and high treatment adoption support regional growth.

Asia Pacific is expected to witness strong growth because of rising cancer prevalence, improving healthcare infrastructure, increasing disposable income, and greater awareness. Japan's market reached USD 1.03 billion in 2025, while China is expected to register strong growth.

Europe is projected to experience considerable growth, supported by high disease prevalence and increasing adoption of advanced therapies. The U.K., France, and Spain are among the important markets.

Latin America is expected to grow steadily, while the Middle East and Africa are projected to show comparatively limited growth initially but increasing potential over the longer term.

Key Industry Players

Major companies include Genentech, Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Sanofi, Merck Sharp & Dohme Corp., Taiho Pharmaceutical, Bayer AG, Regeneron Pharmaceuticals, Novartis AG, and Ipsen Biopharmaceuticals.

Recent Industry Developments

In December 2024, the European Commission approved the combination of Opdivo and Yervoy as a first-line treatment for certain MSI-H or dMMR metastatic colorectal cancer patients.

In February 2024, KRAZATI received U.S. FDA accelerated approval in combination with cetuximab for previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer.

Investment Analysis and Opportunities

Investment opportunities are expanding across targeted therapies, immunotherapies, personalized medicine, companion diagnostics, and novel combination treatments. Companies with strong oncology pipelines, advanced clinical research capabilities, and innovative drug-development strategies are positioned to benefit from the evolving colorectal cancer therapeutics landscape.

Conclusion

The global colorectal cancer therapeutics market is expected to maintain steady expansion due to rising disease prevalence, growing awareness, improved diagnosis, and continuous pharmaceutical innovation. The market is valued at USD 14.41 billion in 2025, projected to reach USD 15.26 billion in 2026, and is expected to reach USD 24.10 billion by 2034. Targeted therapy, advanced immunotherapy, personalized treatment, and growing healthcare investment will remain key factors shaping the colorectal cancer therapeutics market outlook through 2034.

Unit Value (USD billion)

Segmentation By Therapy

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Others

By Cancer Type

  • Colorectal Adenocarcinoma
  • Gastrointestinal Carcinoid Tumors
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Colorectal Cancer - By Key Countries, 2025
  • 4.2. Pipeline Analysis, Key Players
  • 4.3. Key Industry Developments
  • 4.4. New Product Launches
  • 4.5. Increasing R&D Initiatives in Colorectal Cancer Diagnostics

5. Global Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Therapy
    • 5.2.1. Targeted Therapy
    • 5.2.2. Immunotherapy
    • 5.2.3. Chemotherapy
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.3.1. Colorectal Adenocarcinoma
    • 5.3.2. Gastrointestinal Carcinoid Tumors
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Therapy
    • 6.2.1. Targeted Therapy
    • 6.2.2. Immunotherapy
    • 6.2.3. Chemotherapy
    • 6.2.4. Others
  • 6.3. Market Analysis - By Cancer Type
    • 6.3.1. Colorectal Adenocarcinoma
    • 6.3.2. Gastrointestinal Carcinoid Tumors
    • 6.3.3. Others
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
    • 6.4.4. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Therapy
    • 7.2.1. Targeted Therapy
    • 7.2.2. Immunotherapy
    • 7.2.3. Chemotherapy
    • 7.2.4. Others
  • 7.3. Market Analysis - By Cancer Type
    • 7.3.1. Colorectal Adenocarcinoma
    • 7.3.2. Gastrointestinal Carcinoid Tumors
    • 7.3.3. Others
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
    • 7.4.4. Others
  • 7.5. Market Analysis - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Therapy
    • 8.2.1. Targeted Therapy
    • 8.2.2. Immunotherapy
    • 8.2.3. Chemotherapy
    • 8.2.4. Others
  • 8.3. Market Analysis - By Cancer Type
    • 8.3.1. Colorectal Adenocarcinoma
    • 8.3.2. Gastrointestinal Carcinoid Tumors
    • 8.3.3. Others
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
    • 8.4.4. Others
  • 8.5. Market Analysis - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Therapy
    • 9.2.1. Targeted Therapy
    • 9.2.2. Immunotherapy
    • 9.2.3. Chemotherapy
    • 9.2.4. Others
  • 9.3. Market Analysis - By Cancer Type
    • 9.3.1. Colorectal Adenocarcinoma
    • 9.3.2. Gastrointestinal Carcinoid Tumors
    • 9.3.3. Others
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
    • 9.4.4. Others
  • 9.5. Market Analysis - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Colorectal Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Therapy
    • 10.2.1. Targeted Therapy
    • 10.2.2. Immunotherapy
    • 10.2.3. Chemotherapy
    • 10.2.4. Others
  • 10.3. Market Analysis - By Cancer Type
    • 10.3.1. Colorectal Adenocarcinoma
    • 10.3.2. Gastrointestinal Carcinoid Tumors
    • 10.3.3. Others
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
    • 10.4.4. Others
  • 10.5. Market Analysis - By Country/ Sub-Region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles
    • 11.5.1. Genentech, Inc.
      • 11.5.1.1. Overview
      • 11.5.1.2. Products & Services
      • 11.5.1.3. SWOT Analysis
      • 11.5.1.4. Recent Developments
      • 11.5.1.5. Strategies
      • 11.5.1.6. Financials
    • 11.5.2. Eli Lilly and Company
      • 11.5.2.1. Overview
      • 11.5.2.2. Products & Services
      • 11.5.2.3. SWOT Analysis
      • 11.5.2.4. Recent Developments
      • 11.5.2.5. Strategies
      • 11.5.2.6. Financials
    • 11.5.3. Pfizer Inc.
      • 11.5.3.1. Overview
      • 11.5.3.2. Products & Services
      • 11.5.3.3. SWOT Analysis
      • 11.5.3.4. Recent Developments
      • 11.5.3.5. Strategies
      • 11.5.3.6. Financials
    • 11.5.4. Sanofi
      • 11.5.4.1. Overview
      • 11.5.4.2. Products & Services
      • 11.5.4.3. SWOT Analysis
      • 11.5.4.4. Recent Developments
      • 11.5.4.5. Strategies
      • 11.5.4.6. Financials
    • 11.5.5. Teva Pharmaceutical Industries Ltd.
      • 11.5.5.1. Overview
      • 11.5.5.2. Products & Services
      • 11.5.5.3. SWOT Analysis
      • 11.5.5.4. Recent Developments
      • 11.5.5.5. Strategies
      • 11.5.5.6. Financials
    • 11.5.6. Bristol Myers Squibb
      • 11.5.6.1. Overview
      • 11.5.6.2. Products & Services
      • 11.5.6.3. SWOT Analysis
      • 11.5.6.4. Recent Developments
      • 11.5.6.5. Strategies
      • 11.5.6.6. Financials
    • 11.5.7. Merck Sharp & Dohme Corp.
      • 11.5.7.1. Overview
      • 11.5.7.2. Products & Services
      • 11.5.7.3. SWOT Analysis
      • 11.5.7.4. Recent Developments
      • 11.5.7.5. Strategies
      • 11.5.7.6. Financials
    • 11.5.8. Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
      • 11.5.8.1. Overview
      • 11.5.8.2. Products & Services
      • 11.5.8.3. SWOT Analysis
      • 11.5.8.4. Recent Developments
      • 11.5.8.5. Strategies
      • 11.5.8.6. Financials
    • 11.5.9. Bayer AG
      • 11.5.9.1. Overview
      • 11.5.9.2. Products & Services
      • 11.5.9.3. SWOT Analysis
      • 11.5.9.4. Recent Developments
      • 11.5.9.5. Strategies
      • 11.5.9.6. Financials
    • 11.5.10. Regeneron Pharmaceuticals, Inc.
      • 11.5.10.1. Overview
      • 11.5.10.2. Products & Services
      • 11.5.10.3. SWOT Analysis
      • 11.5.10.4. Recent Developments
      • 11.5.10.5. Strategies
      • 11.5.10.6. Financials
    • 11.5.11. Novartis AG
      • 11.5.11.1. Overview
      • 11.5.11.2. Products & Services
      • 11.5.11.3. SWOT Analysis
      • 11.5.11.4. Recent Developments
      • 11.5.11.5. Strategies
      • 11.5.11.6. Financials
    • 11.5.12. Ipsen Biopharmaceuticals, Inc.
      • 11.5.12.1. Overview
      • 11.5.12.2. Products & Services
      • 11.5.12.3. SWOT Analysis
      • 11.5.12.4. Recent Developments
      • 11.5.12.5. Strategies
      • 11.5.12.6. Financials

12. Appendix

List of Tables

  • Table 1: Global Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 2: Global Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 3: Global Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 6: North America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 7: North America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 10: Europe Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 11: Europe Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 14: Asia Pacific Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 15: Asia Pacific Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 18: Latin America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 19: Latin America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 22: Middle East & Africa Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
  • Table 23: Middle East & Africa Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Colorectal Cancer Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Colorectal Cancer Therapeutics Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Colorectal Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 3: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Targeted Therapy, 2021-2034
  • Figure 4: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Immunotherapy, 2021-2034
  • Figure 5: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Chemotherapy, 2021-2034
  • Figure 6: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 7: Global Colorectal Cancer Therapeutics Market Value Share (%), by Cancer Type, 2025 & 2034
  • Figure 8: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Colorectal Adenocarcinoma, 2021-2034
  • Figure 9: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Gastrointestinal Carcinoid Tumors, 2021-2034
  • Figure 10: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 11: Global Colorectal Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 12: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 13: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 14: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 15: Global Colorectal Cancer Therapeutics Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 16: Global Colorectal Cancer Therapeutics Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 17: North America Colorectal Cancer Therapeutics Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 18: North America Colorectal Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 19: North America Colorectal Cancer Therapeutics Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 20: North America Colorectal Cancer Therapeutics Market Value Share (%), by Cancer Type, 2025
  • Figure 21: North America Colorectal Cancer Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 22: North America Colorectal Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 23: North America Colorectal Cancer Therapeutics Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 24: North America Colorectal Cancer Therapeutics Market Value Share (%), By Country, 2025
  • Figure 25: Europe Colorectal Cancer Therapeutics Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 26: Europe Colorectal Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 27: Europe Colorectal Cancer Therapeutics Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 28: Europe Colorectal Cancer Therapeutics Market Value Share (%), by Cancer Type, 2025
  • Figure 29: Europe Colorectal Cancer Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 30: Europe Colorectal Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 31: Europe Colorectal Cancer Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 32: Europe Colorectal Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 33: Asia Pacific Colorectal Cancer Therapeutics Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 34: Asia Pacific Colorectal Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 35: Asia Pacific Colorectal Cancer Therapeutics Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 36: Asia Pacific Colorectal Cancer Therapeutics Market Value Share (%), by Cancer Type, 2025
  • Figure 37: Asia Pacific Colorectal Cancer Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 38: Asia Pacific Colorectal Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 39: Asia Pacific Colorectal Cancer Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 40: Asia Pacific Colorectal Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 41: Latin America Colorectal Cancer Therapeutics Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 42: Latin America Colorectal Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 43: Latin America Colorectal Cancer Therapeutics Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 44: Latin America Colorectal Cancer Therapeutics Market Value Share (%), by Cancer Type, 2025
  • Figure 45: Latin America Colorectal Cancer Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 46: Latin America Colorectal Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 47: Latin America Colorectal Cancer Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 48: Latin America Colorectal Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 49: Middle East & Africa Colorectal Cancer Therapeutics Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 50: Middle East & Africa Colorectal Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 51: Middle East & Africa Colorectal Cancer Therapeutics Market Value (US$ Mn), by Cancer Type, 2025 & 2034
  • Figure 52: Middle East & Africa Colorectal Cancer Therapeutics Market Value Share (%), by Cancer Type, 2025
  • Figure 53: Middle East & Africa Colorectal Cancer Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Colorectal Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Colorectal Cancer Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Colorectal Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Colorectal Cancer Therapeutics Market Share (%), By Company, 2025